Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | REGN6569 |
Synonyms | |
Therapy Description |
REGN6569 is a monoclonal antibody that binds to and activates the glucocorticoid-induced tumor necrosis factor receptor (GITR, TNFRSF18) expressed on immune cells, potentially leading to activation and proliferation of effector T cells and anti-tumor immune response (J Clin Oncol 42, 2024 (suppl 16; abstr 2650, NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
REGN6569 | REGN-6569|REGN 6569 | GITR Antibody 7 | REGN6569 is a monoclonal antibody that binds to and activates the glucocorticoid-induced tumor necrosis factor receptor (GITR, TNFRSF18) expressed on immune cells, potentially leading to activation and proliferation of effector T cells and anti-tumor immune response (J Clin Oncol 42, 2024 (suppl 16; abstr 2650, NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|